¼¼°èÀÇ ½Å¼Ó °Ë»ç ½ÃÀå
Rapid Tests
»óǰÄÚµå : 1546154
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 171 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å¼Ó °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 490¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 326¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å¼Ó °Ë»ç ¼¼°è ½ÃÀåÀº 2023-2030³â°£ CAGR 6.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 490¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ º´¿øÃ¼ °Ë»ç´Â CAGR 6.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 241¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯ÀüÀÚ ÀçÁ¶ÇÕ °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 88¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ ½Å¼Ó °Ë»ç ½ÃÀåÀº 2023³â¿¡ 88¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 110¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¾î ºÐ¼® ±â°£ÀÎ 2023-2030³â°£ CAGR Àº 9.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.0%¿Í 6.4%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½Å¼Ó °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

½Å¼Ó °Ë»ç´Â ÀÇ·á Áø´Ü¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿À°í Àִ°¡?

½Å¼Ó°Ë»ç´Â ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ¿© Àû½Ã¿¡ ÀÇ»ç°áÁ¤°ú Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Çö´ë ÀÇ·á Áø´ÜÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ƯÁ¤ º´¿øÃ¼, ¹ÙÀÌ¿À¸¶Ä¿, Ç×üÀÇ Á¸À縦 ¸î ºÐ¿¡¼­ ¸î ½Ã°£ ³»¿¡ °¨ÁöÇϵµ·Ï ¼³°èµÇ¾î ƯÈ÷ Áï°¢ÀûÀÎ °á°ú°¡ Áß¿äÇÑ ÀÓ»ó ÇöÀå¿¡¼­ ¸Å¿ì À¯¿ëÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ½Å¼Ó°Ë»ç´Â Äڷγª19, µ¶°¨, HIV, ¸»¶ó¸®¾Æ µî °¨¿°¼º ÁúȯÀÇ Áø´Ü°ú ´ç´¢º´, ½ÉÇ÷°ü Áúȯ µî ¸¸¼ºÁúȯÀÇ ¸ð´ÏÅ͸µ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½Å¼Ó °Ë»çÀÇ Æí¸®ÇÔ°ú ½Å¼Ó¼ºÀº ÀÇ·áÁøÀÌ È¯ÀÚÀÇ »óŸ¦ ½Å¼ÓÇÏ°Ô Æò°¡Çϰí, ÀûÀýÇÑ Ä¡·á¸¦ ½ÃÀÛÇϰí, °¨¿° È®»êÀ» ¹æÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ È¿À²¼º°ú ȯÀÚ Áß½ÉÀÇ Ä¡·á¸¦ Á¡Á¡ ´õ ¿ì¼±½ÃÇÔ¿¡ µû¶ó ½Å¼Ó °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ½Å¼Ó °Ë»çÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ½Å¼Ó °Ë»çÀÇ Á¤È®¼º, ¹Î°¨µµ, Á¢±Ù¼ºÀ» Å©°Ô Çâ»ó½ÃÄÑ ´Ù¾çÇÑ Áø´Ü ¿ëµµÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í, PCRÀ» ÀÌ¿ëÇÑ ½Å¼Ó °Ë»ç¿Í °°Àº ºÐÀÚÁø´Ü ¹æ¹ýÀÇ °³¹ßÀº º´¿øÃ¼ °ËÃâÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Å©°Ô Çâ»ó½ÃÄÑ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °¡´ÉÇÏ°Ô ÇÏ¿´½À´Ï´Ù. ¸é¿ª ÃøÁ¤ ±â¼úÀÇ ¹ßÀüÀº ȯÀÚ °Ëü¿¡¼­ ¹Ì·®ÀÇ Ç׿ø ¹× Ç×ü¸¦ °ËÃâÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ½Å¼Ó °Ë»çÀÇ Á¤È®µµ Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Áø´Ü Ç÷§ÆûÀÇ ¼ÒÇüÈ­¿Í µðÁöÅÐ ±â¼ú°úÀÇ ÅëÇÕÀº ½Å¼Ó °Ë»çÀÇ »ç¿ë ¹üÀ§¸¦ ´õ¿í È®´ëÇÏ¿© ¿ø°ÝÁö ¹× ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­µµ »ç¿ëÇÒ ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå Áø·á °Ë»ç ÀåºñÀÇ µîÀåÀ¸·Î ½Å¼ÓÇÑ Áø´ÜÀÌ È¯ÀÚ¿¡°Ô ´õ °¡±îÀÌ ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾î Áß¾Ó ÁýÁᫎ ½ÇÇè½ÇÀÇ Çʿ伺ÀÌ ÁÙ¾îµé°í Áø·á¼Ò, ¾à±¹, ½ÉÁö¾î °¡Á¤¿¡¼­µµ ½Ç½Ã°£ ÀÇ»ç °áÁ¤ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ½Å¼Ó °Ë»ç¸¦ ³Î¸® äÅÃÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°Ç°­°ü¸®¿¡¼­ ½Å¼Ó°Ë»çÀÇ ÁÖ¿ä ¿ëµµ¿Í ÀåÁ¡Àº ¹«¾ùÀΰ¡?

·¡Çǵå Å×½ºÆ®´Â ´Ù¾çÇÑ ÇコÄÉ¾î ¿ëµµ¿¡ »ç¿ëµÇ¾î ȯÀÚ ¿¹Èĸ¦ °³¼±Çϰí, ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϸç, ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ Å« ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. °¨¿°¼º Áúȯ Áø´Ü¿¡¼­ ½Å¼Ó°Ë»ç´Â º´¿ø±ÕÀ» ½Å¼ÓÇÏ°Ô ½Äº°Çϰí Ä¡·á ¹× °¨¿° ´ëÃ¥À» Áï°¢ÀûÀ¸·Î ½ÃÇàÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÀ±Þ ÀÇ·á¿¡¼­ ½Å¼Ó°Ë»ç´Â ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿, Ç÷´ç µî ȯÀÚÀÇ »óÅ¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÏ¿© »ý¸íÀ» ±¸ÇÒ ¼ö ÀÖ´Â Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ½Å¼Ó°Ë»ç´Â HIV ¹× °£¿° °Ë»ç¿Í °°Àº ¼±º°°Ë»ç ÇÁ·Î±×·¥¿¡¼­µµ Á¶±â ¹ß°ß°ú Ä¡·á·ÎÀÇ ¿¬°áÀ» ÃËÁøÇÏ´Â ±ÍÁßÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, ½Å¼Ó °Ë»ç´Â ¸¸¼º Áúȯ °ü¸®¿¡µµ »ç¿ëµÇ¾î ȯÀÚÀÇ °Ç°­ »óŸ¦ ½Ç½Ã°£À¸·Î µ¥ÀÌÅÍÈ­ÇÏ¿© º¸´Ù °³ÀÎÈ­µÈ »çÀü ¿¹¹æÀû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ½Å¼Ó °Ë»çÀÇ ÁÖ¿ä ÀåÁ¡Àº ¼Óµµ, »ç¿ë ÆíÀǼº, Àü¹® Àåºñ³ª ´ë±Ô¸ð ±³À° ¾øÀ̵µ Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡À¸·Î ÀÎÇØ ½Å¼Ó °Ë»ç´Â Àû½Ã¿¡ È¿°úÀûÀΠȯÀÚ Ä¡·á¸¦ Áö¿øÇÏ´Â Çö´ë ÀÇ·á¿¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ¾ú½À´Ï´Ù.

½Å¼Ó °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å¼Ó °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¨¿°¼º Áúȯ Áõ°¡¿Í ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺Àº ÀÇ·á ½Ã½ºÅÛÀÌ ¹ßº´À» ¾ïÁ¦Çϰí Àû½Ã¿¡ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó Áß¿äÇÑ ÃËÁøÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü, ¸é¿ªºÐ¼®, ÇöÀåÁø´Ü(point-of-care) °Ë»çÀÇ ±â¼ú ¹ßÀüÀº ½Å¼Ó °Ë»çÀÇ Á¤È®¼º, ¹Î°¨µµ, Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ºÐ»êµÈ ȯÀÚ Á᫐ Áø·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½Å¼Ó °Ë»ç µµÀÔÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â Áø·á¼Ò, ¾à±¹, °¡Á¤ µî ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ½Ç½Ã°£ Áø´ÜÀÌ °¡´ÉÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, °ËÁø ÇÁ·Î±×·¥ÀÇ È®´ë¿Í ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½Å¼Ó °Ë»ç°¡ Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ð´ÏÅ͸µ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ´Ù´Â Á¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Áø´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å°ú ÇÔ²² ½Å¼Ó °Ë»ç ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 38°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Rapid Tests Market to Reach US$49.0 Billion by 2030

The global market for Rapid Tests estimated at US$32.6 Billion in the year 2023, is expected to reach US$49.0 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2023-2030. Pathogen Tests, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$24.1 Billion by the end of the analysis period. Growth in the GMOs Tests segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.8 Billion While China is Forecast to Grow at 9.9% CAGR

The Rapid Tests market in the U.S. is estimated at US$8.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$11.0 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Rapid Tests Market - Key Trends and Drivers Summarized

How Are Rapid Tests Revolutionizing Healthcare Diagnostics?

Rapid tests have become a cornerstone of modern healthcare diagnostics, offering quick and accurate results that enable timely decision-making and treatment. These tests are designed to detect the presence of specific pathogens, biomarkers, or antibodies in a matter of minutes to hours, making them invaluable tools in clinical settings, particularly in situations where immediate results are crucial. Rapid tests are widely used for diagnosing infectious diseases such as COVID-19, influenza, HIV, and malaria, as well as for monitoring chronic conditions like diabetes and cardiovascular diseases. The convenience and speed of rapid tests allow healthcare providers to quickly assess a patient's condition, initiate appropriate treatment, and prevent the spread of infectious diseases. As healthcare systems increasingly prioritize efficiency and patient-centered care, the demand for rapid tests continues to grow.

How Are Technological Advancements Enhancing the Accuracy and Accessibility of Rapid Tests?

Technological advancements are significantly enhancing the accuracy, sensitivity, and accessibility of rapid tests, making them more reliable and widely available for various diagnostic applications. The development of molecular diagnostics, such as PCR-based rapid tests, has greatly improved the sensitivity and specificity of pathogen detection, enabling the identification of diseases at an early stage. Advances in immunoassay technology have also contributed to the improved accuracy of rapid tests by allowing the detection of minute quantities of antigens or antibodies in patient samples. The miniaturization and integration of diagnostic platforms with digital technologies have further expanded the reach of rapid tests, enabling their use in remote and resource-limited settings. Additionally, the rise of point-of-care testing devices has brought rapid diagnostics closer to patients, reducing the need for centralized laboratories and enabling real-time decision-making in clinics, pharmacies, and even homes. These technological innovations are driving the widespread adoption of rapid tests in healthcare systems worldwide.

What Are the Key Applications and Benefits of Rapid Tests in Healthcare?

Rapid tests are used in a wide range of healthcare applications, offering significant benefits that improve patient outcomes, streamline workflows, and reduce healthcare costs. In infectious disease diagnostics, rapid tests enable the quick identification of pathogens, allowing for the immediate implementation of treatment and infection control measures. In emergency care settings, rapid tests provide critical information on a patient's condition, such as cardiac biomarkers or blood glucose levels, enabling timely interventions that can save lives. Rapid tests are also valuable in screening programs, such as HIV or hepatitis testing, where they facilitate early detection and linkage to care. Additionally, rapid tests are used in chronic disease management, where they provide real-time data on a patient's health status, allowing for more personalized and proactive care. The primary benefits of rapid tests include their speed, ease of use, and ability to provide accurate results without the need for specialized equipment or extensive training. These advantages make rapid tests essential tools in modern healthcare, supporting timely and effective patient care.

What Factors Are Driving the Growth in the Rapid Tests Market?

The growth in the Rapid Tests market is driven by several factors. The increasing prevalence of infectious diseases and the need for quick and accurate diagnostics are significant drivers, as healthcare systems seek to contain outbreaks and provide timely treatment. Technological advancements in molecular diagnostics, immunoassays, and point-of-care testing are also propelling market growth by improving the accuracy, sensitivity, and accessibility of rapid tests. The rising demand for decentralized and patient-centered care is further boosting the adoption of rapid tests, as these tools enable real-time diagnostics in various healthcare settings, including clinics, pharmacies, and homes. Additionally, the expansion of screening programs and the growing focus on preventive healthcare are contributing to market growth, as rapid tests play a crucial role in early detection and monitoring of diseases. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Rapid Tests market.

Select Competitors (Total 38 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â